Description

DAYVIGO 10 MG

Indications

DAYVIGO (lemborexant) is indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. It is designed to help improve sleep quality and duration, thereby enhancing overall sleep satisfaction. DAYVIGO is particularly beneficial for individuals who experience insomnia that affects their daytime functioning and quality of life.

Mechanism of Action

DAYVIGO is classified as a dual orexin receptor antagonist (DORA). It works by selectively blocking the activity of orexin A and orexin B, neuropeptides that play a crucial role in regulating wakefulness and arousal. By inhibiting these receptors, DAYVIGO promotes sleep onset and maintenance, thereby facilitating a natural sleep cycle without the addictive properties associated with some traditional sedative-hypnotics.

Pharmacological Properties

DAYVIGO is rapidly absorbed after oral administration, with peak plasma concentrations typically occurring within 1 to 4 hours. The drug exhibits linear pharmacokinetics, meaning that its concentration in the bloodstream increases proportionally with the dose. The half-life of DAYVIGO is approximately 17 to 19 hours, allowing for a sustained effect that can help individuals maintain sleep throughout the night. It is primarily metabolized by the liver, with cytochrome P450 enzymes playing a significant role in its clearance. The drug is excreted mainly in the urine, with a small fraction eliminated in feces.

Contraindications

DAYVIGO is contraindicated in patients with a known hypersensitivity to lemborexant or any of the excipients in the formulation. It should not be used in individuals with severe hepatic impairment, as this could lead to increased plasma concentrations and a higher risk of adverse effects. Additionally, caution is advised in patients with a history of substance use disorders or those who are currently using other central nervous system depressants.

Side Effects

Common side effects associated with DAYVIGO include somnolence, headache, dizziness, and fatigue. These effects are generally mild to moderate in intensity and may diminish over time as the body adjusts to the medication. Serious side effects, although rare, can include complex sleep behaviors such as sleepwalking, sleep driving, or engaging in other activities while not fully awake. Patients should be monitored for any unusual changes in behavior or sleep patterns while taking DAYVIGO.

Dosage and Administration

The recommended starting dose of DAYVIGO is 10 mg taken orally once per night, approximately 30 minutes before bedtime. Depending on individual response and tolerability, the dose may be increased to a maximum of 20 mg. It is important for patients to take DAYVIGO only when they can dedicate a full night to sleep (7 hours or more) to minimize the risk of next-day impairment. DAYVIGO should not be taken with or immediately after a meal, as food may affect its absorption and efficacy.

Interactions

DAYVIGO has the potential to interact with other medications, particularly those that are metabolized by the cytochrome P450 enzyme system. Co-administration with strong CYP3A inhibitors, such as ketoconazole or ritonavir, may increase the plasma concentration of lemborexant, necessitating a dose reduction. Conversely, strong CYP3A inducers, like rifampin, may decrease the effectiveness of DAYVIGO. Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs and herbal supplements, to avoid potential interactions.

Precautions

Patients should exercise caution when using DAYVIGO, particularly those with a history of respiratory disorders, as the drug may exacerbate conditions such as sleep apnea. Additionally, elderly patients may be more sensitive to the effects of DAYVIGO and may require dose adjustments. It is advisable for patients to avoid consuming alcohol or other CNS depressants while taking DAYVIGO, as this can increase the risk of sedation and impairment. Pregnant or breastfeeding women should consult their healthcare provider before starting DAYVIGO, as the safety of the drug in these populations has not been established.

Clinical Studies

Clinical studies have demonstrated the efficacy of DAYVIGO in improving sleep onset and maintenance in patients with insomnia. In randomized, double-blind, placebo-controlled trials, patients treated with DAYVIGO reported significant improvements in sleep latency and total sleep time compared to those receiving placebo. The studies also indicated that DAYVIGO was well-tolerated, with a safety profile similar to that of other sleep medications. Long-term studies have shown sustained efficacy over extended periods, suggesting that DAYVIGO can be an effective option for chronic insomnia management.

Conclusion

DAYVIGO 10 mg is a valuable treatment option for adults suffering from insomnia, offering a novel mechanism of action through dual orexin receptor antagonism. Its pharmacological properties, including a favorable safety profile and efficacy in improving sleep parameters, make it a suitable choice for many patients. As with any medication, it is essential for patients to work closely with their healthcare provider to determine the best treatment plan for their individual needs and to monitor for any potential side effects or interactions.